Revvity (RVTY) AI Stock Analysis

• Market Cap: $12.34B
• Dividend Yield: 0.29%
• Average Volume (3M): 1.13M
• Price to Earnings (P/E): 52.9
• Beta (1Y): 0.82
• Revenue Growth: 3.37%
• EPS Growth: -18.80%
• Country: US
• Employees: 11,000
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 1.70
• Shares Outstanding: 113,375,620
• 10 Day Avg. Volume: 1,360,071
• 30 Day Avg. Volume: 1,126,316
• PEG Ratio: -3.33
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 3.96
• P/FCF Ratio: 21.97
• Enterprise Value/Market Cap: 1.22
• Enterprise Value/Revenue: 5.28
• Enterprise Value/Gross Profit: 10.52
• Enterprise Value/Ebitda: 19.67
• 1Y Price Target: $110.75
• Price Target Upside: 3.42% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 9
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 64 Neutral
• Price Target: $115.00 ▲(7.39% Upside)

The score is primarily driven by solid financial performance led by strong free-cash-flow generation and improved leverage, tempered by weaker profitability versus prior years. Technicals are constructive longer term but show near-term consolidation. Valuation is the biggest constraint due to the high P/E and low yield, while the latest earnings call supports a moderately positive view with steady EPS/FCF outlook but only modest growth and near-term margin pressure.

Positive Factors

Strong free cash flow generation

Consistent high free cash flow and strong cash conversion provide durable financial flexibility for reinvestment, M&A, and shareholder returns. This underpins capital allocation, de-leveraging and resilience through cycles despite prior volatility in 2023.

Improved balance sheet and low-rate debt

De-leveraging and a fixed-rate, low-cost debt profile reduce refinancing and interest-rate risk, preserving strategic optionality. This durable capital structure improvement supports future M&A, R&D investment, and cushions near-term earnings variability.

High-growth recurring software revenue

Rapid SaaS ARR growth and >110% net retention signal durable, sticky recurring revenue with higher lifetime value. As software becomes a larger mix, revenue visibility, margin expansion potential and cross-sell opportunities improve long-term earnings quality.

Negative Factors

Modest organic growth outlook

A low single-digit organic growth framework constrains revenue scalability over the medium term. Even with product initiatives and acquisitions, limited near-term demand implies slower top-line leverage on fixed costs and restrains long-term revenue trajectory.

Near-term margin pressure and step-down

Material margin compression and an anticipated Q1 trough indicate structural cost pressures and slower realization of efficiency programs. Rising below‑the‑line costs and FX/tariff exposure could sustainably weigh on operating leverage and free cash generation.

China diagnostics end‑market weakness

Sustained DRG-driven declines in China create a prolonged headwind in a meaningful end market, reducing growth optionality and increasing geographic concentration risk. Recovery timelines into mid‑2026 imply limited near-term upside from this region.

Revvity Business Overview & Revenue Model

Company Description

Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

How the Company Makes Money

Revvity generates revenue primarily through a subscription-based model for its software products, which provides clients with ongoing access to its analytics and AI tools. Additionally, the company earns income from professional services, including implementation, training, and consulting, which help clients to effectively integrate and utilize its technologies. Revvity also benefits from strategic partnerships with major tech firms and industry leaders, which enhance its market reach and provide additional revenue opportunities through joint ventures and co-branded offerings. Furthermore, the company may explore revenue from licensing its technology to third-party developers and organizations, further diversifying its income streams.

Revvity Financial Statement Overview

Summary

Financial quality is supported by strong and improving free cash flow (notably rebounding in 2024–2025) and a balance sheet that has de-levered from prior peaks, but profitability has downshifted versus 2020–2022 and revenue growth has only recently stabilized.

Income Statement

Revenue has stabilized after a sharp decline in 2022–2023, with flat growth in 2024 and modest improvement in 2025. Profitability, however, has weakened versus the strong 2020–2022 period: net profit margin stepped down from ~17–19% (2020–2022) to ~8–11% (2024–2025), and operating profit also compressed. Gross margin remains healthy overall, but the multi-year downshift in operating and bottom-line profitability keeps the score in the middle range.

Balance Sheet

The company has a sizable equity base and assets relative to debt, with debt-to-equity improving from higher levels in 2021–2022 to a more moderate level in 2024 (latest calculable). Total debt has also trended down from 2021–2022 peaks, supporting financial flexibility. The main drawback is leverage still being meaningful in absolute dollars, and some latest-year leverage/return metrics are unavailable in the provided data.

Cash Flow

Cash generation is a key strength: free cash flow is consistently positive and generally tracks well against earnings (free cash flow to net income ~0.86–0.93 in 2020–2022 and 2024–2025). After a very weak 2023 cash flow year, operating cash flow and free cash flow rebounded strongly in 2024–2025, indicating improving conversion and resilience. The primary risk is the notable volatility shown in 2023, which suggests cash flows can fluctuate materially year to year.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.86B	2.76B	2.75B	3.31B	3.83B
Gross Profit	1.52B	1.32B	1.32B	1.76B	2.28B
EBITDA	643.66M	840.25M	713.56M	1.18B	1.62B
Net Income	241.68M	295.83M	-118.38M	569.18M	943.16M
Balance Sheet
Total Assets	12.17B	12.39B	13.56B	14.13B	15.00B
Cash, Cash Equivalents and Short-Term Investments	919.87M	1.16B	1.60B	454.36M	603.32M
Total Debt	3.37B	3.33B	4.07B	4.60B	5.16B
Total Liabilities	4.92B	4.73B	5.69B	6.75B	7.86B
Stockholders Equity	7.25B	7.67B	7.87B	7.38B	7.14B
Cash Flow
Free Cash Flow	515.43M	541.65M	9.90M	594.18M	1.32B
Operating Cash Flow	588.96M	628.30M	91.27M	679.81M	1.41B
Investing Cash Flow	-17.35M	776.16M	1.31B	-132.85M	-4.11B
Financing Cash Flow	-855.05M	-1.13B	-947.12M	-661.80M	2.94B

Revvity Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 107.09
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RVTY, the sentiment is Neutral. The current price of 107.09 is below the 20-day moving average (MA) of 109.84, above the 50-day MA of 103.52, and above the 200-day MA of 94.96, indicating a neutral trend. The MACD of 2.50 indicates Positive momentum. The RSI at 48.54 is Neutral, neither overbought nor oversold. The STOCH value of 21.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RVTY.

Revvity Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
QGEN	73 Outperform	$11.10B	27.50	11.29%	3.31%	5.32%	336.29%
EXAS	70 Outperform	$19.53B	-19.28	-34.54%	―	14.47%	-353.69%
DGX	69 Neutral	$20.81B	21.95	13.69%	1.80%	13.74%	14.87%
ILMN	68 Neutral	$22.13B	31.62	31.20%	―	-2.39%	―
RVTY	64 Neutral	$12.34B	52.88	3.04%	0.29%	3.37%	-18.80%
GH	58 Neutral	$14.75B	-35.76	―	―	30.38%	24.17%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Revvity Corporate Events

Revvity Raises 2025 Outlook With Strong Preliminary Results

On January 12, 2026, Revvity said it will report its fourth-quarter and full-year 2025 results before the market opens on February 2, 2026, followed by an earnings call led by CEO Prahlad Singh and CFO Max Krakowiak, and confirmed that Singh is scheduled to present at the J.P. Morgan Healthcare Conference on January 13, 2026. The company issued preliminary figures indicating fourth-quarter 2025 reported and organic revenue growth of about 6% and 4%, respectively, implying roughly $772 million in sales, and full-year 2025 reported and organic revenue growth of about 4% and 3%, respectively, for approximately $2.855 billion in revenue, while also indicating that adjusted earnings per share for 2025 are now expected to come in above the previously guided upper end of $5.00, signaling operational outperformance and a stronger earnings profile heading into 2026.

The most recent analyst rating on (RVTY) stock is a Buy with a $120.00 price target. To see the full list of analyst forecasts on Revvity stock, see the RVTY Stock Forecast page.